Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Immunity Project

Immunity Project

Developing a free HIV vaccine through hacking its lifecycle for global immunity.

: 11
: Seed
: Y Combinator W14

Immunity Project, founded with the mission to eradicate HIV/AIDS, is a non-profit initiative focused on developing a free HIV vaccine. By hacking the HIV life cycle, they aim to create a vaccine that empowers individuals with the same resistance as HIV controllers. Their vision is to provide this vaccine globally at no cost, significantly impacting public health and advancing the fight against HIV/AIDS.

Notable affiliated individuals include leading scientists and researchers in the field of immunology and virology. The project has garnered attention and support from various philanthropic organizations and private investors committed to global health. Key achievements include successful preclinical trials demonstrating the vaccine's potential efficacy. The Immunity Project's innovative approach and commitment to accessibility have positioned it as a transformative force in the global effort to combat HIV/AIDS.

Similar Companies

Adventris Pharmaceuticals

adventris.com

FruitVaccine

fruitvaccine.org

Eradivir

eradivir.com

Coalition for Epidemic Preparedness Innovations

cepi.net

ImmunArtes

InvVax

inv-vax.com

VitriVax

vitrivaxbio.com

GeoVax Labs

geovax.com

Centivax

centivax.com

Vaxxinity

vaxxinity.com

Inimmune

inimmune.com

NeuImmune

neuimmune.com

Epivax

epivax.com

CellChorus

cellchorus.com

ImmunityBio

immunitybio.com

Quick Facts

Who are Immunity Project's competitors?

Companies similar to Immunity Project include Adventris Pharmaceuticals, FruitVaccine, Eradivir and Coalition for Epidemic Preparedness Innovations.

When was Immunity Project's last funding round?

Immunity Project's most recent funding round was for $120k (USD) in January 2014.

How much disclosed funding has Immunity Project raised?

As of Jan 1, 2014, Immunity Project has disclosed funding of $120k (USD). Undisclosed round amounts are excluded.

How many employees does Immunity Project have?

Immunity Project has 11 employees as of Aug 23, 2023.

Classification

Ownership: Venture-backed
Technology: Biotech

Customer: Non-Profit
Main Product: HIV Vaccine

Tags: Healthtech